R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Affiliations

• ¹ Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
• ² Department of Hematology, Treant Hospital, Emmen, The Netherlands.
• ³ Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
• ⁴ Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands.
• ⁵ Department of Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.
• ⁶ Department of Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
• ⁷ Department of Hematology, Cancer Center, UMC Utrecht, Utrecht, The Netherlands.
• ⁸ Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
• ⁹ Department of Hematology, Haga Teaching Hospital, The Hague, The Netherlands.
• ¹⁰ Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
• ¹¹ Department of Hematology, Haaglanden Medical Center, The Hague, The Netherlands.
• ¹² Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
• ¹³ Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands. m.nijland@umcg.nl.